| scholarly article | Q13442814 |
| P50 | author | JoAnn E. Manson | Q6204013 |
| Tsuyoshi Hamada | Q89223117 | ||
| Reiko Nishihara | Q95974375 | ||
| Jonathan A Nowak | Q114578182 | ||
| Marios Giannakis | Q114578217 | ||
| Thing Rinda Soong | Q117275727 | ||
| Shuji Ogino | Q18055035 | ||
| P2093 | author name string | Li Liu | |
| Andrew T Chan | |||
| Yin Cao | |||
| Douglas A Mata | |||
| Iny Jhun | |||
| P2860 | cites work | Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells | Q40352933 |
| SNP rs16906252C>T Is an Expression and Methylation Quantitative Trait Locus Associated with an Increased Risk of Developing MGMT-Methylated Colorectal Cancer. | Q40716298 | ||
| Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer | Q40757402 | ||
| Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability | Q40850728 | ||
| Realizing the Potential of Cancer Prevention - The Role of Implementation Science | Q42198794 | ||
| Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer | Q54215360 | ||
| Two Federal Agencies Tighten Rules for Clinical Trials | Q89001090 | ||
| Why most published research findings are false | Q21092395 | ||
| How to make more published research true | Q24288766 | ||
| Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review | Q24289005 | ||
| Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science | Q24289208 | ||
| Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease | Q24289344 | ||
| 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers | Q24318523 | ||
| CpG Island Methylation in Colorectal Cancer: Past, Present and Future | Q24597977 | ||
| Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field | Q24620628 | ||
| Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology | Q24622814 | ||
| Interdisciplinary research has consistently lower funding success | Q25271761 | ||
| Molecular phenotypes of colorectal cancer and potential clinical applications | Q26785725 | ||
| Cancer prevention as part of precision medicine: 'plenty to be done' | Q26995183 | ||
| Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology | Q27011884 | ||
| Towards the introduction of the 'Immunoscore' in the classification of malignant tumours | Q27026489 | ||
| Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. | Q27851408 | ||
| KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. | Q27851616 | ||
| Obesity and colorectal cancer: molecular features of adipose tissue | Q28079556 | ||
| Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum | Q28262150 | ||
| Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival | Q28277824 | ||
| Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer | Q28299100 | ||
| Statistical methods for studying disease subtype heterogeneity | Q28385063 | ||
| A new initiative on precision medicine | Q29615654 | ||
| Proceedings of the third international molecular pathological epidemiology (MPE) meeting | Q30238962 | ||
| Bioactive Nutrients and Nutrigenomics in Age-Related Diseases | Q30239072 | ||
| Imaging biomarker roadmap for cancer studies | Q30242020 | ||
| Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. | Q30244608 | ||
| Chasing the personalized medicine dream through biomarker validation in colorectal cancer | Q30244949 | ||
| Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis | Q30248900 | ||
| Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD) | Q33648694 | ||
| Epidemiological transition of colorectal cancer in developing countries: environmental factors, molecular pathways, and opportunities for prevention | Q33661094 | ||
| Aspirin use and survival after diagnosis of colorectal cancer | Q33764480 | ||
| Immune cells: plastic players along colorectal cancer progression | Q33985586 | ||
| The role of epidemiology in the era of molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of Epidemiologic Research Symposium | Q34376200 | ||
| Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations | Q34390505 | ||
| Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin | Q37413259 | ||
| Biomarkers in precision therapy in colorectal cancer. | Q37609130 | ||
| Important molecular genetic markers of colorectal cancer. | Q37619856 | ||
| Aspirin and colorectal cancer: back to the future | Q37626475 | ||
| Aspirin as adjuvant therapy for colorectal cancer—reinterpreting paradigms | Q38036541 | ||
| Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates | Q38147841 | ||
| Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis | Q38252696 | ||
| Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients | Q38445688 | ||
| Drug repurposing in oncology--patient and health systems opportunities. | Q38611707 | ||
| A comparison of statistical methods for the study of etiologic heterogeneity. | Q38658332 | ||
| PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies | Q38681826 | ||
| Aspirin and colorectal cancer: the promise of precision chemoprevention. | Q38730064 | ||
| Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype | Q38761790 | ||
| Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention | Q38771344 | ||
| Precancer Atlas to Drive Precision Prevention Trials. | Q38857539 | ||
| Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. | Q38938955 | ||
| Integrative analysis of the colorectal cancer proteome: potential clinical impact | Q38947015 | ||
| Transforming Growth Factor β Superfamily Signaling in Development of Colorectal Cancer | Q38988997 | ||
| Developing drugs that target the Wnt pathway: recent approaches in cancer and neurodegenerative diseases | Q39037684 | ||
| Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer | Q39066439 | ||
| Fusobacterium nucleatum in Colorectal Carcinoma Tissue According to Tumor Location | Q39217446 | ||
| Immunotherapy for colorectal cancer: where are we heading? | Q39218636 | ||
| Cancer subtypes in aetiological research | Q39397286 | ||
| Nutrition, inflammation and cancer | Q39443978 | ||
| Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. | Q39542382 | ||
| Evaluation of PTGS2 Expression, PIK3CA Mutation, Aspirin Use and Colon Cancer Survival in a Population-Based Cohort Study | Q40225671 | ||
| Long-term use of antibiotics and risk of colorectal adenoma | Q40257973 | ||
| Challenges and opportunities in international molecular cancer prevention research: An ASPO Molecular Epidemiology and the Environment and International Cancer Prevention Interest Groups Report. | Q34441501 | ||
| Proceedings of the second international molecular pathological epidemiology (MPE) meeting | Q34475686 | ||
| Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review | Q34551974 | ||
| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 | ||
| The increasing dominance of teams in production of knowledge | Q34618686 | ||
| Association between molecular subtypes of colorectal cancer and patient survival | Q34759064 | ||
| PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival | Q34778710 | ||
| 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis | Q35033202 | ||
| PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer | Q35236785 | ||
| Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants | Q35246178 | ||
| Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. | Q35332074 | ||
| Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. | Q35383553 | ||
| The utility of Aspirin in dukes C and high risk dukes B colorectal cancer - The ASCOLT study: study protocol for a randomized controlled trial | Q35735849 | ||
| A Meta-Regression Method for Studying Etiological Heterogeneity Across Disease Subtypes Classified by Multiple Biomarkers. | Q35896952 | ||
| Association between body mass index and mortality for colorectal cancer survivors: overall and by tumor molecular phenotype | Q35920915 | ||
| Colorectal cancer: a tale of two sides or a continuum? | Q35935945 | ||
| The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism | Q35955534 | ||
| Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer | Q36051807 | ||
| A prospective study of bisphosphonate use and risk of colorectal cancer | Q36212417 | ||
| Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. | Q36345775 | ||
| Integration of molecular pathology, epidemiology and social science for global precision medicine | Q36463854 | ||
| Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation | Q36551145 | ||
| Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin | Q36678527 | ||
| The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. | Q36896165 | ||
| Review Article: The Role of Molecular Pathological Epidemiology in the Study of Neoplastic and Non-neoplastic Diseases in the Era of Precision Medicine | Q36968401 | ||
| Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer | Q36989392 | ||
| Cancer Prevention: Obstacles, Challenges and the Road Ahead. | Q37002946 | ||
| Aspirin use and risk of colorectal cancer according to BRAF mutation status | Q37094281 | ||
| Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location | Q37111201 | ||
| Transforming Cancer Prevention through Precision Medicine and Immune-oncology. | Q37114360 | ||
| Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention | Q37139174 | ||
| The prognostic value of Microsatellite Instability, KRAS, BRAF and PIK3CA mutations in stage II colon cancer patients | Q37170486 | ||
| Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. | Q37360360 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | pharmacology | Q128406 |
| data science | Q2374463 | ||
| P577 | publication date | 2017-12-06 | |
| P1433 | published in | npj Precision Oncology | Q50817392 |
| P1476 | title | Integration of pharmacology, molecular pathology, and population data science to support precision gastrointestinal oncology | |
| P478 | volume | 1 |
| Q57822921 | Dysbiosis of the gut microbiota and colorectal cancer: the key target of molecular pathological epidemiology |
| Q62494554 | Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology |
| Q50043586 | Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine |
| Q89097041 | TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas |
| Q59796444 | The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome |
Search more.